Get to Know Dr. Daniel Landau
Dr. Daniel Landau is a distinguished board-certified hematologist/oncologist who has served in leadership roles and helped to innovate telehealth services at Orlando Health Cancer Institute. In September 2023, he began seeing patients in a telehealth role at the Medical University of South Carolina in Charleston.
Landau formerly served as the section chief of hematology and oncology at Orlando Health UF Health Cancer Center beginning in 2018. He started the telehealth program at Orlando Health that continues to offer virtual visits to people with cancer.
He has a longstanding commitment to medical education and fostering passion in the next generation of oncologists. For more than a decade, he has dedicated much of his time and expertise to training physicians.
Landau earned a medical degree in 2005 from the College of Medicine at the University of South Florida in Tampa. In 2008, he completed a residency there in internal medicine. He finished a fellowship at MD Anderson Cancer Center’s Orlando, Florida, campus (now Orlando Health Cancer Institute) in 2011.
His medical interests extend beyond hematology and oncology. Landau has specialized in genitourinary cancers, including cancers of the bladder, prostate and kidney. He has a passion for education, innovation and meeting the unique needs of people facing a cancer diagnosis.
Publications of Dr. Landau
- Hyperfractionated cyclophosphamide as urgent therapy: A single institution experience. Journal of Clinical Oncology, 2017.
- Compliance with Expert Recommendations of Sickle Cell Pain Management—a Single Institution Review. American Society of Hematology, 2017.
- A Single Institution of Review of Patients Complaints and Compliments. Journal of Clinical Oncology, 2016.
- The appropriateness of flow cytometry testing: A single institution retrospective analysis. Journal of Clinical Oncology, 2016.
- Increased Outpatient Care Can Reduce Hospital Stays for Sickle Cell Patients. American Society of Hematology, 2015.
Dr. Landau’s Medical Report Contributions
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England Journal of Medicine, 2018.
- Molecular genetic testing patterns for patients with newly diagnosed acute myeloid leukemia (AML) enrolled in the CONNECT MDS/AML disease registry. Journal of Clinical Oncology, 2017.
Dr. Landau’s Role as Medical Reviewer on Asbestos.com
Landau’s experience with mesothelioma, research and board certifications in oncology, internal medicine and hematology are crucial to his role as a reviewer of medical information.
He makes sure the subject matter and content on Asbestos.com informational pages meet medical and scientific standards.